Triple-Negative Breast Cancer: Marina's Survivor Story

Patient Info: Marina, Female, Under 40

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Triple-negative breast cancer survivor with a BRCA1 mutation who completed treatment after an initial diagnosis and a second diagnosis at the 5-year mark; no formal stage or metastatic disease was stated in the available source text.

The Patient StoryRead more →

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Christina's Patient Story

Patient Info: Christina, Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Liver; lymph nodes

Christina was living with Stage IV HER2-positive metastatic breast cancer. Treatment had cleared the liver disease and removed the visible breast tumor, but small armpit lymph-node disease required radiation and she continued IV treatment every 3 weeks.

The Patient StoryRead more →

ER-positive/HER2-positive breast cancer with rare paranasal sinus and skull metastasis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and paranasal sinus metastasis were ER positive, PR negative, HER2 positive; GATA3 supported breast origin in metastasis.

Metastatic Site: left frontal sinus; ethmoid air cells; posterior…

The paranasal sinus/skull metastasis did not respond to palliative radiotherapy; her condition deteriorated and she died 2 years after her initial presentation to the treating facility.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Jacqueline's Patient Story

Patient Info: Jacqueline Bennett, Female, Under 40

Biomarkers: Initial ER-negative, PR-negative, HER2-negative; later HER2-positive

Jacqueline completed treatment for initial Stage IA triple-negative breast cancer during pregnancy and later developed a HER2-positive, hormone receptor-negative breast cancer. After 3 of 6 current treatments, the tumor was no longer visible on ultrasound or MRI, with targeted therapy and double mastectomy still planned.

The Patient StoryRead more →

Triple-negative breast cancer diagnosed during pregnancy: remission

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

The patient remains in remission 30 months after surgery. Immune-related brachial plexopathy after treatment improved after steroids, IVIG, and plasmapheresis, with electrophysiologic resolution and near-complete strength and sensory recovery.

PubMed CentralRead more →

Invasive lobular breast cancer with colonic metastases treated with colectomy and capecitabine

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Breast and colon metastatic samples were ER+ and HER2-; PR varied by sample

Metastatic Site: colon; perivisceral lymph nodes

After laparoscopic left colectomy and capecitabine for colonic metastases, follow-up showed no clinical or radiological evidence of recurrence or progression at 8 months postoperatively.

PubMed CentralRead more →

Non-metastatic metaplastic triple-negative breast cancer with residual disease after chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Metaplastic triple-negative breast cancer; HER2 0

The patient had an initial partial response to neoadjuvant chemotherapy but then progressed before surgery. Modified radical mastectomy found substantial residual metaplastic carcinoma with 0/21 nodes involved, followed by adjuvant radiotherapy and metronomic capecitabine.

PubMed CentralRead more →

Stage III HER2-Positive Breast Cancer: Caroline's Patient Story

Patient Info: Caroline McNally, Female, Under 40 | Stage III

Biomarkers: Hormone-positive component reported; exact ER/PR/HER2 panel not stated

As of February 2026, Caroline was in active treatment for Stage III hormone-positive breast cancer, receiving Taxol after dose-dense AC and preparing for double mastectomy, likely radiation, and hormone therapy.

Stage 4 breast cancer: 4 years and counting

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor: hormone receptor-positive; HER2 1+. Metastatic recurrence: triple-negative breast cancer.

Metastatic Site: liver, bone, lung, supraclavicular lymph nodes,…

After response of choroidal metastases to eye radiation plus sacituzumab govitecan, disease progressed in February 2023 with cerebellar and pituitary brain lesions; she developed obstructive hydrocephalus, entered hospice in May 2023, and died in June 2023.

PubMed CentralRead more →

Stage IIIB triple-negative metaplastic breast cancer: urgent mastectomy and reconstruction after rapid progression on neoadjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; nuclear grade 3

At 18-month follow-up, she was disease-free after urgent mastectomy, axillary dissection, flap/skin-graft reconstruction, resumed chemotherapy, and radiation for rapidly progressive triple-negative metaplastic breast cancer.

PubMed CentralRead more →

Stage IIB breast cancer with severe radiation recall after abemaciclib

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2 1+ / HER2-negative

The flap healed after abemaciclib was stopped and the tissue expander/patch were removed, but her long-term cancer-control and reconstruction outcomes were not yet reported.

PubMed CentralRead more →

Metastatic triple-negative breast cancer with sacituzumab-govitecan pneumonitis and progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lung

Sacituzumab-govitecan pneumonitis improved with corticosteroids and half-dose rechallenge did not reproduce pneumonitis, but follow-up CT showed one new pulmonary metastasis and enlargement of previous lung metastases; PFS on sacituzumab govitecan was 5.37 months.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer: Chase's Survivor Story

Patient Info: Chase, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative

As of January 2026, Chase had shown no evidence of cancer for nearly 5 years after Stage IIB triple-negative breast cancer treatment and had completed 3 investigational vaccine injections without significant side effects.

Cleveland ClinicRead more →

Stage II Invasive Lobular Carcinoma: Tamra's Patient Story

Patient Info: Tamra, Female | Stage II

Biomarkers: MammaPrint genomic analysis pending/under consideration

As of January 2026, Tamra had chosen partial mastectomy with radiation and concurrent bilateral reconstruction for Stage II invasive lobular breast cancer, with chemotherapy decision dependent on MammaPrint results.

Lobular Breast Cancer AllianceRead more →

Breast cancer survivor developed Ramsay Hunt syndrome with vertigo

Patient Info: Anonymized, Female, 60s

Biomarkers: Breast cancer biomarkers not reported. Ramsay Hunt syndrome was diagnosed clinically.

Breast cancer treatment had been completed years earlier. The later neurological episode improved partially after antiviral therapy, steroids, pain control, betahistine, acupuncture, and vestibular rehabilitation, with mild residual dizziness and facial weakness at 3 months.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Sonja's Patient Story

Patient Info: Sonja Rideout, Female | Stage IV

Biomarkers: HER2-positive; Tempus testing later indicated immunotherapy as an option

Metastatic Site: Lungs; liver; bone: tailbone; thoracic lymph nodes

As of January 2026, Sonja was living with metastatic HER2-positive breast cancer after spread to lungs and liver, later tailbone and thoracic lymph nodes, and had moved to weekly carboplatin/gemcitabine plus monthly immunotherapy.

Stage IV triple-negative invasive lobular breast cancer with HER2 mutations: complete metabolic response to trastuzumab deruxtecan

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Triple-negative invasive lobular breast cancer with HER2-low/dubious staining and HER2 FISH-negative; somatic ERBB2/HER2 and mutations.

Metastatic Site: iliac bone lesions / bone metastases

As of January 2026, metastatic triple-negative invasive lobular breast cancer with HER2 mutations had a sustained complete metabolic response to trastuzumab deruxtecan for 20 months, with dose reduction for neutropenia and no pulmonary toxicity.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Sian's Survivor Story

Patient Info: Sian Bevans, Female, 50s | Stage II

Biomarkers: Triple-positive

Sian was 11 years past diagnosis, completed 10 years of maintenance medication in May 2025, and reported feeling more like herself; no recurrence was described.

Cleveland ClinicRead more →

Metastatic breast cancer history with pacing-induced cardiomyopathy and heart-function recovery

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: sternum; ribs

She had osseous metastatic breast cancer involving the sternum and ribs, while pacing-induced cardiomyopathy improved clinically and biventricular function recovered completely at 6 months on medical therapy.

PubMed CentralRead more →

Stage 2 breast cancer: lump discovered at 61, successful treatment

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Breast neuroendocrine tumor was ER/PR strongly positive, HER2 1+

Metastatic Site: lung, mediastinal lymph nodes, bone (ribs, spine,…

After Stage IIA primary breast neuroendocrine tumor treated with lumpectomy, sentinel lymph-node biopsy, radiation, and short-duration anastrozole, the patient developed metastatic recurrence about 2 years later, declined additional therapy, entered hospice, and died 1 month later.

PubMed CentralRead more →

Male breast cancer history complicated by suspected bone disease and later IgG-kappa multiple myeloma

Patient Info: Anonymized, Male, 60s | Stage I

Biomarkers: Breast cancer was ER/PR-positive and HER2-negative by FISH. Later workup showed IgG-kappa multiple myeloma with IgH rearrangement.

The patient achieved very good partial response after KBD and completed autologous hematopoietic stem cell transplantation with engraftment, but later died of a novel coronavirus infection.

PubMed CentralRead more →

Stage I HR-Positive Invasive Lobular Carcinoma: Erica's Survivor Story

Patient Info: Erica, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative

As of December 2025, Erica had Stage IA ER-positive/PR-positive/HER2-negative ILC removed with negative lymph nodes, completed 16 rounds of radiation, and was focused on survivorship and advocacy.

Lobular Breast Cancer AllianceRead more →

Breast cancer history with incidental adult cystic nephroma: no renal recurrence after nephrectomy

Patient Info: Anonymized, Female, 40s

Biomarkers: Breast cancer biomarkers not reported. Kidney cystic nephroma showed PAX8 in epithelium and PR in stroma, ER absent.

As of December 2025, the kidney lesion had been resected and proven to be adult cystic nephroma rather than breast cancer metastasis, with no clinical symptoms or radiologic recurrence at 1-year follow-up.

PubMed CentralRead more →